



COLLEGE of AMERICAN
PATHOLOGISTS

Surveys and Anatomic Pathology Education Programs

Performance Improvement Program in Surgical Pathology

PIP/PIPW-A 2019

Participant Summary

This document is available online in e-LAB Solutions Suite.

© **CAP 2019**. The CAP does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The CAP hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The CAP prohibits use of the material in the Report — and any unauthorized use of the CAP's name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The CAP will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the CAP's name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

**2019 PIP/PIPW-A
PARTICIPANT SUMMARY**

Program Update

This report summarizes the diagnostic responses for set A of the 2019 Performance Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Rochelle A. Simon, MD FCAP, Chair
Aaron Auerbach, MD FCAP, Vice Chair

Oyedele A. Adeyi, MBBS FCAP	Nilsa C. Ramirez, MD FCAP
Vijayalakshmi Ananthanarayanan, MD, MBBS FCAP	Kirtee Raparia, MD FCAP
Phyu Aung, PhD FCAP	Vijaya B. Reddy, MD, MBA FCAP
Deborah Ann Belchis, MD FCAP	Safia N. Salaria, MD FCAP
Rajan Dewar, MD, PhD FCAP	Robert A. Schwartz, MD FCAP
Leslie Dodd, MD FCAP	Sabrina C. Sopha, MD FCAP
Raul Gonzalez, MD FCAP	Nichole L. Steidler, MD FCAP
Christina Isacson, MD FCAP	Justin M. Wells, MD FCAP
Xiaoyin Jiang, MD FCAP	Danielle E. Westfall, MD FCAP
Archi Patel, MD-J	

Case # 2019-01

Diagnosis

(5597) Nephroblastoma with heterologous elements (teratoid Wilms' tumor)

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2388	Cellular mesoblastic nephroma	26	0.4	11	6.2
1020	Cystic partially-differentiated nephroblastoma	119	1.9	57	32.2
5596	Intrarenal teratoma	8	0.1	17	9.6
1666	Metanephric adenoma	16	0.3	6	3.3
5597	Nephroblastoma with heterologous elements (teratoid Wilms' tumor)	5995	96.7	85	48.0
1012	Neuroblastoma	39	0.6	1	0.6

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2887	51.7
002		1223	21.9
003	Satisfactory	1354	24.2
004		110	2.0
005	Unsatisfactory	11	0.2

Case # 2019-02

Diagnosis

(2540) Fibroma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2081	Adult granulosa cell tumor	3	0.1	7	4.3
1711	Brenner tumor	1	<0.1	1	0.6
1957	Endometrial stromal sarcoma	5	0.1	4	2.5
2540	Fibroma	6000	96.6	91	56.2
1100	Fibrothecoma	152	2.5	46	28.4
1646	Leiomyoma	14	0.2	8	4.9
1697	Massive ovarian edema	1	<0.1	0	0.0
2548	Thecoma	28	0.5	5	3.1

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2593	46.7
002		1205	21.7
003	Satisfactory	1490	26.9
004		233	4.2
005	Unsatisfactory	29	0.5

Diagnosis

(5600) Mitochondrial cardiomyopathy

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5598	Arrhythmogenic cardiomyopathy	10	0.2	0	0.0
5599	Glycogen storage disorder	65	1.1	28	17.7
5600	Mitochondrial cardiomyopathy	6078	98.0	113	71.6
5601	Mucopolysaccharidoses	43	0.7	17	10.7
1122	Myocarditis	2	<0.1	0	0.0

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2748	49.7
002		1243	22.5
003	Satisfactory	1392	25.2
004		129	2.3
005	Unsatisfactory	18	0.3

Diagnosis

(5603) TFE3-associated renal cell carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2632	Clear cell papillary renal cell carcinoma	55	0.9	15	9.7
1665	Clear cell renal cell carcinoma	60	1.0	18	11.6
5602	Multilocular cystic renal cell neoplasm of low malignant potential	3	<0.1	2	1.3
1797	Papillary renal cell carcinoma	11	0.2	1	0.6
5603	TFE3-associated renal cell carcinoma	6069	97.9	119	76.8

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2540	46.1
002		1278	23.2
003	Satisfactory	1485	27.0
004		184	3.3
005	Unsatisfactory	22	0.4

Case # 2019-05

Diagnosis

(2485) Hepatocellular carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5604	Dysplastic nodule	11	0.2	8	5.3
2484	Focal nodular hyperplasia	10	0.2	3	2.0
2485	Hepatocellular carcinoma	6172	99.5	135	90.1
2277	Intrahepatic cholangiocarcinoma	4	<0.1	2	1.3
1518	Macroregenerative cirrhotic nodule	4	<0.1	2	1.3

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2822	51.7
002		1196	21.9
003	Satisfactory	1320	24.2
004		102	1.9
005	Unsatisfactory	18	0.3

Case # 2019-06

Diagnosis

(5605) Poorly differentiated squamous cell carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2658	Large cell carcinoma	16	0.3	4	2.7
1165	Melanoma	1	<0.1	0	0.0
1421	Pleomorphic carcinoma	23	0.4	9	6.1
1368	Poorly differentiated adenocarcinoma	121	2.0	13	9.0
5605	Poorly differentiated squamous cell carcinoma	6038	97.4	120	82.2

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2552	46.7
002		1207	22.0
003	Satisfactory	1485	27.1
004		205	3.7
005	Unsatisfactory	27	0.5

Case # 2019-07

Diagnosis

(2383) Seminoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2716	Diffuse large B-cell lymphoma, NOS	13	0.2	12	8.3
1994	Embryonal carcinoma	4	<0.1	1	0.7
5607	Monophasic choriocarcinoma	3	<0.1	1	0.7
2383	Seminoma	6153	99.3	126	86.9
2341	Sertoli cell tumor	7	<0.1	1	0.7
5608	Spermatocytic tumor	14	0.2	4	2.7
2467	Yolk sac tumor	2	<0.1	0	0.0

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2800	51.0
002		1190	21.6
003	Satisfactory	1397	25.4
004		106	1.9
005	Unsatisfactory	6	<0.1

Case # 2019-08

Diagnosis

(2256) Well-differentiated liposarcoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1700	Myxoid liposarcoma	7	<0.1	4	2.7
1511	Pleomorphic liposarcoma	17	0.3	3	2.1
5606	Renal angiomyolipoma	6	<0.1	7	4.9
2256	Well-differentiated liposarcoma	6166	99.5	130	90.3

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2611	47.6
002		1257	22.9
003	Satisfactory	1468	26.7
004		138	2.5
005	Unsatisfactory	16	0.3

Case # 2019-09

Diagnosis

(2468) Embryonal rhabdomyosarcoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2424	Adenosarcoma	55	0.9	4	2.8
1698	Aggressive angiomyxoma	68	1.1	27	19.0
1843	Alveolar rhabdomyosarcoma	72	1.2	9	6.3
1951	Carcinosarcoma	9	0.1	3	2.1
2468	Embryonal rhabdomyosarcoma	5991	96.7	99	69.8

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2795	51.2
002		1141	20.9
003	Satisfactory	1396	25.6
004		112	2.0
005	Unsatisfactory	15	0.3

Case # 2019-10

Diagnosis

(5609) Anaplastic thyroid carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5609	Anaplastic thyroid carcinoma	6020	97.2	56	39.4
1620	Malignant melanoma	15	0.2	3	2.1
2048	Medullary thyroid carcinoma	107	1.7	70	49.3
5610	Pleomorphic undifferentiated sarcoma	3	<0.1	1	0.7
2272	Poorly differentiated thyroid carcinoma	43	0.7	12	8.5
1600	Riedel thyroiditis	3	<0.1	0	0.0

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2571	46.9
002		1216	22.1
003	Satisfactory	1488	27.1
004		166	3.0
005	Unsatisfactory	48	0.9



COLLEGE of AMERICAN PATHOLOGISTS

325 Waukegan Road
Northfield, IL 60093-2750
800-323-4040
847-832-7000 (Country code: 001)